Last reviewed · How we verify
ARB-001467
ARB-001467 is an investigational drug that targets the hepatitis B virus.
ARB-001467 is an investigational drug that targets the hepatitis B virus. Used for Chronic hepatitis B.
At a glance
| Generic name | ARB-001467 |
|---|---|
| Sponsor | Arbutus Biopharma Corporation |
| Drug class | Antiviral |
| Target | Hepatitis B virus |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 2 |
Mechanism of action
It works by inhibiting the replication of the virus, which can lead to the reduction of viral load and the alleviation of symptoms associated with hepatitis B infection.
Approved indications
- Chronic hepatitis B
Common side effects
- Fatigue
- Headache
- Nausea
Key clinical trials
- Study of ARB-001467 in Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |